BCL2 and ovarian cancer: Western Blot showed that after treatment of ovarian cancer cells with cisplatin and niraparib, respectively, neither stable overexpression nor stable knockdown of LOC730101 affected the protein expression of BECN1, but after drug treatment, overexpression of LOC730101 compared with the control group, the autophagy marker molecule LC3 II/LC3 I ratio was reduced, while the trend was reversed in the knockdown group, and the anti-apoptotic protein Bcl2 was reduced in the overexpression LOC730101 group compared with the control group (Fig. 4H).